Stock CDMO AVID BIOSERVICES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
7.32 USD +7.17% Intraday chart for Avid Bioservices, Inc. +12.27% +12.62%
Apr. 24 Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Apr. 19 North American Morning Briefing : Stock Futures -2- DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
Avid Bioservices Receives Nasdaq Noncompliance Notice
Avid Bioservices Prices $160 Million Convertible Notes Offering; Shares Slump
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Buoyed by Powell's Comments
Top Premarket Decliners
Avid Bioservices Prices $160 Million Convertible Notes Offering
Avid Bioservices Preliminary Fiscal Q3 Revenue Falls 11%; $160 Million Private Placement of Notes Set; Shares Slump
Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024
USA-Le module spatial privé Odysseus en route vers la Lune
In moon race with China, U.S. setbacks test role of private firms
Avid Bioservices Faces Uphill Battle as Overall Demand Environment Poses Challenges, RBC Says
Sector Update: Health Care Stocks Lean Lower Premarket Friday
November Payrolls Post Bigger Gain Than Expected as Exchange-Traded Funds, Equity Futures Slide Pre-Bell
Sector Update: Health Care
Avid Bioservices Fiscal Q2 Loss Widens, Revenue Falls; Cuts Fiscal 2024 Sales Outlook; Shares Plunge Premarket
Avid Bioservices Fiscal Q2 Loss Widens, Revenue Falls; Fiscal 2024 Revenue Outlook Cut; Shares Slump After Hours
Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024
Avid Bioservices, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
Avid Bioservices Partners with California Institute for Regenerative Medicine to Provide CDMO Services for Cell and Gene Therapy Programs
Avid Bioservices Completes Construction of New Cell, Gene Therapy Facility
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CDMO Stock
  4. News Avid Bioservices, Inc.
  5. Other languages